Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trialsFengcai Zhu, Ningshao Xia, Chunlan Zhuang et al.|The Lancet Respiratory Medicine|2022Cited by 140
Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trialShoujie Huang, Ningshao Xia, Xiaowen Hu et al.|The Lancet|2024Cited by 70
Active surveillance of hepatitis E: a 10-year epidemiological analysis in a city in eastern ChinaXingcheng Huang, Ningshao Xia, Xiaoxiang Zheng et al.|Emerging Microbes & Infections|2024Cited by 11
Long-term protection from naturally acquired immunity against hepatitis E virus reinfectionXiaohui Liu, Ningshao Xia, Xia Zang et al.|Nature Communications|2025Cited by 0